On-Demand webinar: Multiparticulates 7 – Next Generation ODTS with high dosed Multiparticulates
In this webinar Norbert Pöllinger and Tom West presented the unique opportunities offered by the combination of 3D printing and multiparticulates to achieve novel solutions in ODT application. They demonstrated how swallowing issues of high dosed drug products can be overcome and show new ways in the field of patient centric solutions for the whole population.
To give an impression of the webinar content we selected three questions and answers.
See the following short Q+A video snippets:
Q1: Is it recommended to make multiparticulates for 1000mg active indicated dose?
Q2: How do you measure the effectiveness of taste masking in the mouth as it disintegrates so fast in the mouth?
Q3: How about the speed on zip dose? So how much you can produce?
Speakers:
Dr. Norbert Pöllinger
Norbert Poellinger is heading the Technology Department unit. Until 2018, he was responsible for Development and Manufacturing Services Group at Glatt Pharmaceutical Services which included Pharmaceutical Development, Manufacturing, Quality Control, Quality Assurance and Plant Engineering. He studied pharmaceutical sciences at the University of Erlangen, Germany and received a PhD degree in Pharmaceutical Technology. Currently, the recently formed Glatt Pharmaceutical Services GmbH & Co.KG focuses on controlled release and taste masked multiparticulates including minitablets and tablets. Drug products for the paediatric and geriatric population are of particular interest. Logistic services have become a new service opportunity of Glatt.
Thomas G. West
Thomas G. West, M.S., is the Vice President of Pharmaceutical Development at Aprecia Pharmaceuticals LLC, focusing on internal pipeline and partnership/licensing opportunities. For over 20 years he has held positions of escalating responsibility applying 3D Printing to the lifesciences in startup to development-stage companies. His experience includes diverse aspects of novel product and process development, regulatory strategy, intellectual property, and market assessment. Example applications include rapidly disintegrating oral dosage forms, controlled release oral and implantable dosage forms, and synthetic bone graft substitutes. He is a co-inventor on numerous patents related to 3D Printing and co-authored a book chapter outlining the development context for SPRITAM, the first 3D Printed pharmaceutical product to receive FDA approval. Mr. West received his B.S. and M.S. degrees in Chemical Engineering from Rutgers University, and is a registered patent agent.